about
sameAs
Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic DystrophyImmortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cellsGain of RNA function in pathological cases: Focus on myotonic dystrophy.Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy.The dynamism of PABPN1 nuclear inclusions during the cell cycle.PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.Two novel COLVI long chains in zebrafish that are essential for muscle development.Satellite cell dysfunction contributes to the progressive muscle atrophy in myotonic dystrophy type 1.Cells of Matter-In Vitro Models for Myotonic Dystrophy.Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells.PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expressionSelective silencing of mutated mRNAs in DM1 by using modified hU7-snRNAsFISH Protocol for Myotonic Dystrophy Type 1 CellsImprovement of Dystrophic Muscle Fragility by Short-Term Voluntary Exercise through Activation of Calcineurin Pathway in mdx MiceGenome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice
P50
Q28264217-46733493-D8C5-4BA6-BB51-55F6391C0D57Q33588075-C43F9614-390A-466C-A2D5-E956CA37D587Q37164562-C4035A25-FE23-46BF-9C6C-031DD6DB9C14Q37164562-D30ED761-0AD3-4E4F-A27F-DF3B6044453CQ37901735-07604B02-E709-4C44-A013-A443C5BF8ADAQ39533985-6AF845E5-9001-45C0-82EF-3F1B638AC928Q40252477-4ACCC2EF-2C6E-473A-A7DE-4590D0F87827Q40449021-58C30C8E-75BF-43F0-BFAE-8F2AEA90EB40Q40547943-2F827A06-DA4A-488D-9B0A-BA76AC1A22E2Q51829611-093D8B55-CC42-405E-AE4E-91091B2F3AEFQ55100992-B1BBC79B-F5E1-46AB-B8D7-C313C406CAD1Q64947331-EBEEFC57-9C66-465B-8356-7BC2315D9EAAQ80957829-3334EC36-866F-4CD0-AE4B-80EF90813E9AQ83034979-29F62679-87B1-4541-867F-680CA9B7E670Q90500763-FE080B98-5779-428B-823E-580C330E8557Q91127059-93D25F6C-FEA5-4B26-B849-84362FBB77F3Q93114664-FFDADE10-2AA3-45C8-9BB7-96B9EE798925
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3860-7049
@en
name
Arnaud F Klein
@ast
Arnaud F Klein
@en
Arnaud F Klein
@nl
type
label
Arnaud F Klein
@ast
Arnaud F Klein
@en
Arnaud F Klein
@nl
prefLabel
Arnaud F Klein
@ast
Arnaud F Klein
@en
Arnaud F Klein
@nl
P106
P21
P31
P496
0000-0002-3860-7049